Two heads are better than one ! Joint lab heads. Director & Dept Director Breast Cancer Now Research Centre at @icrlondon.bsky.social. Precision Oncology, HRD, PARPi, synthetic lethality, breast & other cancers. Trying to do some damage.
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Our new study is out in Nature Communications.
Using TNBC organoid mouse models, we show that necroptosis in both tumour and stromal compartments cooperatively drives effective responses to immunogenic cell death–based immunotherapy.
🔗 www.nature.com/articles/s41...
@arsenalfc.bsky.social a valiant loss. We took the fight to a skilful team and if were to loose, it wasn’t because we were poorer. Still crying at what might have been. We fight again.
www.biorxiv.org/content/10.6...
Bea has been a stalwart of research at the Breast Cancer Now Centre since its inception. Seeing her contribution recognised like this is great.
Bottled it !
Most advanced triple-negative breast cancers remain resistant to immunotherapy. Here, the authors discover that RIPK1-driven necroptosis in both tumor and stromal compartments is essential for effecti...
If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.
www.linkedin.com/pulse/beatri...
We show that normally germline‑restricted HORMAD1 induces aneuploidy in TNBC by disrupting Aurora B/INCENP and weakening spindle assembly checkpoint. This creates sensitivity to MPS1, Aurora B, and BUB1 inhibitors. Work @icr.ac.uk funded by @breastcancernow.bsky.social and published rdcu.be/e7Som
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
Meier Lab ICR
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
The past two decades of PARP inhibitor synthetic lethality in cancer is explored.
